Candel Therapeutics Statistics
Total Valuation
CADL has a market cap or net worth of $486.36 million. The enterprise value is $333.02 million.
| Market Cap | 486.36M |
| Enterprise Value | 333.02M |
Important Dates
The last earnings date was Thursday, November 12, 2026, after market close.
| Earnings Date | Nov 12, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
CADL has 78.45 million shares outstanding. The number of shares has increased by 39.72% in one year.
| Current Share Class | 78.45M |
| Shares Outstanding | 78.45M |
| Shares Change (YoY) | +39.72% |
| Shares Change (QoQ) | +4.39% |
| Owned by Insiders (%) | 7.38% |
| Owned by Institutions (%) | 61.56% |
| Float | 62.15M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | 196.11 |
| PB Ratio | 3.70 |
| P/TBV Ratio | 3.70 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 7.57, with a Debt / Equity ratio of 0.38.
| Current Ratio | 7.57 |
| Quick Ratio | 7.42 |
| Debt / Equity | 0.38 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -13.30 |
Financial Efficiency
Return on equity (ROE) is -93.65% and return on invested capital (ROIC) is -38.03%.
| Return on Equity (ROE) | -93.65% |
| Return on Assets (ROA) | -33.54% |
| Return on Invested Capital (ROIC) | -38.03% |
| Return on Capital Employed (ROCE) | -44.50% |
| Weighted Average Cost of Capital (WACC) | 3.33% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.80M |
| Employee Count | 55 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +26.02% in the last 52 weeks. The beta is -0.29, so CADL's price volatility has been lower than the market average.
| Beta (5Y) | -0.29 |
| 52-Week Price Change | +26.02% |
| 50-Day Moving Average | 9.75 |
| 200-Day Moving Average | 8.41 |
| Relative Strength Index (RSI) | 30.83 |
| Average Volume (20 Days) | 1,420,276 |
Short Selling Information
The latest short interest is 13.09 million, so 16.68% of the outstanding shares have been sold short.
| Short Interest | 13.09M |
| Short Previous Month | 12.77M |
| Short % of Shares Out | 16.68% |
| Short % of Float | 21.06% |
| Short Ratio (days to cover) | 13.53 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -81.76M |
| Pretax Income | -99.14M |
| Net Income | -99.14M |
| EBITDA | -81.10M |
| EBIT | -81.76M |
| Earnings Per Share (EPS) | -$1.47 |
Balance Sheet
The company has $203.12 million in cash and $49.77 million in debt, with a net cash position of $153.35 million or $1.95 per share.
| Cash & Cash Equivalents | 203.12M |
| Total Debt | 49.77M |
| Net Cash | 153.35M |
| Net Cash Per Share | $1.95 |
| Equity (Book Value) | 131.59M |
| Book Value Per Share | 1.68 |
| Working Capital | 179.97M |
Cash Flow
In the last 12 months, operating cash flow was -$68.91 million and capital expenditures -$1.29 million, giving a free cash flow of -$70.20 million.
| Operating Cash Flow | -68.91M |
| Capital Expenditures | -1.29M |
| Depreciation & Amortization | 654,000 |
| Net Borrowing | 43.71M |
| Free Cash Flow | -70.20M |
| FCF Per Share | -$0.89 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
CADL does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -39.72% |
| Shareholder Yield | -39.72% |
| Earnings Yield | -23.78% |
| FCF Yield | -14.43% |
Analyst Forecast
The average price target for CADL is $17.67, which is 185.00% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $17.67 |
| Price Target Difference | 185.00% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 10 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
| Graham Formula Value | n/a |
| Graham Formula Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |